


## Model Medicines Partners with Sanford Burnham Prebys ON AI-DRIVEN DRUG DISCOVERY



Model Medicines, an AI drug discovery software company, has entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop

drugs for novel antiviral targets.

The collaboration leverages Model Medicines' ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, in conjunction with Sanford Burnham Prebys' identification of novel antiviral targets and deep scientific expertise, to discover and develop new treatments for SARS-CoV-2 and other infectious diseases.

The partnership will initially focus on COVID-19 with a long-term vision of both Sanford Burnham Prebys and Model Medicines to develop and advance broad-spectrum antivirals for the infectious diseases of today and those yet unknown in the future. While pandemics like COVID-19 are

not expected on a yearly basis, it is widely understood that the international community will encounter these pandemics at a significantly higher frequency. There is an immediate and ongoing need to develop broad-spectrum antivirals that are ready to be dosed globally at a moment's notice to meet these challenges. The application of novel, validated therapeutics at the onset of an outbreak has the potential to significantly reduce the loss of life and the disruption to the global economy wrought by future infectious diseases.

Model Medicines has created an infectious disease specific version of their ActivPred AI Drug Discovery Platform that focuses exclusively on identifying safe and effective, non-obvious therapeutics with activity against the novel biological targets identified by Sanford Burnham Prebys. Their digital chemistry drug discovery platform leverages artificial intelligence based on fundamental chemistry to discover drugs active against these novel biological targets that cannot be resolved with traditional high throughput screening approaches.

## Inference Study Reveals Pre-Existing Conditions to Be a Significant Factor in COVID PATIENTS WHO ARE HOSPITALIZED POST-VIRAL CLEARANCE

AI technology implemented by Inference on vast amounts of biomedical data during the COVID-19 pandemic has enabled discoveries with a wide range of implications that contribute to a greater understanding of the virus and, ultimately, are advancing patient care.

A study involving Inference, "Pre-existing conditions are associated with COVID patients hospitalization, despite confirmed clearance of SARS-CoV-2 virus," recently published in *EClinicalMedicine* sheds light on the phenomenon of patients infected with SARS-CoV-2 who have been tested as cleared of the virus yet required hospitalizations.

The study, conducted by Inference data scientists and physicians from Mayo Clinic, indicates that COVID-19 patients hospitalized post-viral clearance had higher rates of pre-COVID acute kidney injury, anemia, and cardiac arrhythmias as underlying conditions. The report also finds that pre-COVID conditions generally associated with poorer outcomes during a SARS-CoV-2 infection — hypertension, asthma, obstructive sleep apnea, obesity, and diabetes — were not significantly increased among patients hospitalized after clearance.

The Inference study conducted a retrospective analysis of 222 COVID patients to compare those who were admitted or readmitted after being cleared of the virus, with those who were hospitalized pre-clearance but were not re-admitted post-clearance. The researchers used Inference state-of-the-artificial intelligence software for the augmented curation of comorbidities and complications, analyzing free-form text data including historical physician notes in the patients studied.

"Inference and Mayo Clinic researchers applied Inference AI-driven technology to unearth insights buried in clinical notes by turning unstructured data into computable data," says Venky Soundararajan, PhD, co-founder and chief scientific officer of Inference. "The results we obtained so rapidly using augmented curation and automation would have taken significantly longer than if done manually."



## Craftly.AI Launches AI-POWERED COPYWRITING PLATFORM

Craftly.AI is a web-based artificial intelligence writing platform that uses natural language processing and machine learning to analyze content research and write original articles that are plagiarism-free.



Craftly.AI recently launched a web-based AI-Powered Copywriter that leverages natural language processing and machine learning to research and write original content in seconds, not weeks.

Craftly is an AI-powered copywriter assistant that automates and transforms a large part of the writing process, so marketers can spend more time doing what they do best. On average, a customer will see more than 200 pieces of digital communication before converting. Artificial intelligence creates programs capable of crafting thousands of pieces of content within minutes. Every piece of content that it generates is 100% original. Craftly works with a Machine Learning algorithm that runs on the breakthrough GPT-3 technology that can understand and emulate human communication style. This fully automatic content generation engine runs completely online, so there is no software to download. It can be used for webpage, social media posts, blog posts, ads, and more. Craftly was originally designed as a platform for social media and marketing teams to create their customer messaging tool kit.

## Antares Pharma Uses AKTANA ENGAGEMENT SOLUTION

Aktana announced the release of a dedicated configuration of their AI offering tailored to the needs of emerging and mid-sized biopharma companies. The new Aktana Contextual Intelligence offering provides commercial teams at any sized organization with the right insights and content at the right time to personalize the healthcare professional (HCP) relationship.

Aktana is empowering innovators such as Antares Pharma with world-class AI technology scoped to bolster internal analytics capabilities and provide critical execution support in the form of a turn-key solution that can evolve as needs change. Leveraging a modular AI approach, commercial teams can easily configure a right size solution for quickly identifying the right targets, predicting the ideal timing and content for maxi-

mum HCP engagement, and prioritizing next best actions that users are most likely to adopt.

Aktana works with more than half of the



# IGNITE

## 2021 PharmaVOICE 100 Celebration

VIRTUAL EVENT

**SEPTEMBER 9, 2021**

### SCHEDULE OF EVENTS

#### ► Fireside Chat Panels

Casual conversations with PharmaVOICE 100s whose passions are ignited by purpose and blazing new frontiers

- 9-10am ET - Sparks of Leadership
- 11-12pm ET - Sparks of Creative
- 1-2pm ET - Sparks of Innovation

#### ► Igniting Change: The Red Jacket Panel

An in-depth conversation with our 2021 Red Jackets who shine their light on a transforming industry

- 3-4pm - A Panel of Red Jackets

#### ► Light it Up Happy Hour

Meet the PharmaVOICE 100s during a fun-filled hour of trivia and prizes

- 4:30pm - Happy Hour with the PV100

*(tentative schedule)*



Join us as the PharmaVOICE 100 share how they spark inspiration, ignite change, and blaze new trails.

Celebrate their personal stories of success and learn what fuels their passion for the industry.



### SPONSORSHIP OPPORTUNITIES

#### Signature Sponsor *(1 available)*

Benefits of Event, Blaze, and Spark Sponsorships, 5 admission tickets ... plus opportunity to introduce the Red Jacket Panel (up to 3 minutes)

#### Blaze Sponsor *(11 available)*

Benefits of Event and Spark Sponsorships, 3 admission tickets ... plus seat on one of the panels







#### Spark Sponsor *(Unlimited quantity available)*

Benefits of Event Sponsorship, 2 admission tickets ... plus Spark video

#### Event Sponsor *(Unlimited quantity available)*

Branding on event website and marketing materials, 1 admission ticket ... plus "Looking for Inspiration" quote which will be featured during the event and on event emails

#### \*Event Sponsor Benefits

-  Company branding on the event registration page
-  Company branding during panels
-  Company branding on event emails
-  Social media exposure
-  Branding on OnDemand videos
-  Company branding featured in an event wrap-up in the October issue of PharmaVOICE

For more details or to secure a sponsorship, contact Lisa Banket, Publisher, at 609-730-0196 or lbanket@pharmavoices.com; Suzanne Besse at 561-465-5102 or sbesse@pharmavoices.com; or Amy Bishop at 267-374-8891 or abishop@pharmavoices.com.

(c) PharmaLinx LLC. Rights do not include promotional use.  
For distribution or printing rights, contact mwash@pharmavoice.com



In today's complex healthcare environment, achieving the most productive marketing posture can be challenging. Fortunately, Calcium provides a unique balance of strategic, scientific, creative, and digital expertise that can center

## NaMOoste

your focus, stretch your resources, and elevate brand performance to a higher plane. We're committed to going to the mat for our clients. But we'll ensure that the process is as serene as possible. So experience a (nourishing) breath of fresh air by contacting:

Steven.Michaelson@CalciumUSA.com  
or 917-612-3290.

**calcium**  
BRAND NOURISHMENT



CalciumUSA.com